Benzothiophene-based selective estrogen receptor downregulators

A method of treating an estrogen-related disorder in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula:

• or a pharmaceutically acceptable salt thereof;
• wherein:
• m is 0, 1, 2, 3, or 4;
• n is 0, 1, 2, 3, or 4;
• XA is —O—;
• Ring B is phenyl, naphthyl, quinolinyl, 5- or 6-membered monocyclic heteroaryl, or 7-, 8-, 9- or 10 membered bicyclic heterocyclyl;
• Ring C is phenyl, thiophenyl, 5- or 6-membered monocyclic heteroaryl, or 7-, 8-, 9-, or 10-membered bicyclic heterocyclyl;
• R1 is selected from hydroxyl, hydrogen, halogen, —O(C1-C6 alkyl), —OC(O)(C1-C6 alkyl), —OC(O)C6H5, —OC(O)O(C1-C6 alkyl), —OC(O)OC6H5, and —OSO2(C2-C6 alkyl);
• R2 is selected from —CH═CHCOOH, —NH(CO)COOH, —COOH, C2-C6alkenylene-COOH, and C2-C6alkynylene-COOH;
• R3 is independently selected at each occurrence from hydrogen, halogen, —CN, —NO2, C1-C6alkyl, and C1-C6fluoroalkyl;
• and
• R4 is independently selected at each occurrence from hydrogen, halogen, hydroxyl, C1-C6alkyl, C1-C6fluoroalkyl, —CN, —O(C1-C6 alkyl), and —O(C1-C6fluoroalkyl).